Sunday, September 28, 2025 11:42:18 PM
Will be very interesting tomorrow! 🆙🐂💲
Bullish
Recent NLSP News
- NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute • PR Newswire (US) • 11/17/2025 12:00:00 PM
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger • PR Newswire (US) • 10/30/2025 08:15:00 PM
- NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs • PR Newswire (US) • 10/30/2025 11:00:00 AM
- NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger • PR Newswire (US) • 10/29/2025 11:00:00 AM
- NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem • PR Newswire (US) • 10/29/2025 10:00:00 AM
- NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares • PR Newswire (US) • 10/29/2025 07:53:00 AM
- NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies • PR Newswire (US) • 10/27/2025 11:00:00 AM
- NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 • PR Newswire (US) • 10/23/2025 10:01:00 AM
- NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting • PR Newswire (US) • 09/30/2025 11:00:00 AM
- Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger • PR Newswire (US) • 09/10/2025 10:00:00 AM
- NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients • PR Newswire (US) • 09/04/2025 11:38:00 AM
- NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy • PR Newswire (US) • 07/17/2025 11:00:00 AM
- NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing • PR Newswire (US) • 06/30/2025 11:00:00 AM
- NLS Pharmaceutics CEO Issues Letter to Shareholders • PR Newswire (US) • 06/16/2025 11:00:00 AM
- NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting • PR Newswire (US) • 05/21/2025 11:30:00 AM
